@entity1205 (Taxotere) has been studied at a dose of 100 mg/m2 i.v. as a one hour infusion every 3 weeks, in four phase II trials in @entity1 with extensively pretreated @entity43 . A total of 340 @entity1 were treated, including 256 @entity1 in two separate EORTC (European Organization for Research and Treatment of @entity5 ) trials and 84 @entity1 in two trials in the U.S.A. All @entity1 had received prior @entity900 or @entity3003 therapy and the treatment-free interval was less than 4 months in 155 @entity1 . The overall response rate using conventional UICC criteria was 30% among 315 evaluable cases (95% confidence interval: 24-36%). Among 155 @entity1 whose disease was most refractory (i.e. treatment-free interval was less than 4 months), the overall response rate was 28% (95% confidence interval: 19-36%). Response duration ranged from 4 to 17 months. Grade IV @entity1398 was a common finding and fluid retention was observed. The incidence of @entity1398 ranged from 8 to 44% of @entity1 with two deaths (i.e. 0.6% of the total treated) related to @entity1398 . @entity1205 and @entity1311 ( @entity1311 ) have comparable activities in @entity43 . Ongoing studies with @entity1205 include its use in @entity1 as part of first-line therapy, as well as in @entity1 refractory to @entity1311 . To prevent the development of fluid retention, these now involve the routine use of @entity134 prophylaxis. It is expected that @entity1205 will prove to be an important addition to the drugs available for the treatment of @entity43 .

Phase II trials of @entity1205 (Taxotere) in advanced XXXX --an updated overview.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Taxol'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'neutropenic sepsis', 'febrile neutropenia'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['Docetaxel', 'docetaxel']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']
